Semaglutide (Wegovy) Treatment for Trichotillomania

NCT07282769 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide (Wegovy) can help reduce hair-pulling behaviors in adults with trichotillomania.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 10 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-05 · est. completion 2027-02

What this study is testing ClinicalTrials.gov NCT07282769 ↗

Description as written by the study sponsor.

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Treatments tested

Semaglutide also known as Wegovy Drug

All participants in the study will receive semaglutide (Wegovy).

Main thing measured	NIMH Trichotillomania Severity Scale
Sponsor	University of Chicago
Conditions studied	Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07282769 ↗